Pancragen
Aliases: Lys-Glu-Asp-Trp · KEDW
Last verified: 2026-09-23
The short version
A pancreas-series tetrapeptide — support of pancreatic function and glucose metabolism in the elderly. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian studies of metabolism in the elderly. Status: research chemical. Not approved in the West.
Identity & type
- Molecular type
- bioregulator
- Origin
- A pancreas-series tetrapeptide — support of pancreatic function and glucose metabolism in the elderly.
Mechanism of action
Pancreatic-cell gene regulation; preclinical endocrine-function improvement.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Pancragen. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–5 mg/day SC in courses. A pancreatic bioregulator: Russian reports of metabolic support in the elderly/diabetics; subtle effects.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A pancreatic bioregulator: Russian reports of metabolic support in the elderly/diabetics; subtle effects.
Protocol — official vs community
Official / label
No approved protocol exists. Pancragen is a research peptide bioregulator (Lys-Glu-Asp-Trp) with no registered drug product in any major market.
Duration: —
Russian studies of metabolism in the elderly; preclinical endocrine-function claims without registered human trials.
Community (anecdotal)
1–5 mg SC daily for 10–20 days.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
The regimen is the shared Khavinson course pattern; only the pancreas/glucose-metabolism targeting claim differs from the rest of the series.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Russian studies of metabolism in the elderly.
Preclinical evidence
Russian studies of metabolism in the elderly.
Known risks
- None reported.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.